Skip to main content

Advertisement

Table 1 The relationship between m6A enzyme mRNA expression and clinicopathological parameters with breast cancer. (Data from bc-GenExMiner v4.0)

From: Changes of N6-methyladenosine modulators promote breast cancer progression

Parameter Status METTL3 METTL14 WTAP KIAA1429 FTO ALKBH5
No. mRNA No. mRNA No. mRNA No. mRNA No. mRNA No. mRNA
Age ≤51 1302 1 810 1 1303 1 548 1 1192 1 766 1
> 51 2051 Nc 1673 Nc 2051 Nc 959 Nc 1896 Nc 1546 Up**
ER (IHC) 1488 1 949 1 1376 1 453 1 1383 1 892 1
+ 3810 Up*** 2374 Up*** 3588 Down*** 1282 Up*** 3650 Up*** 2261 Up**
PR (IHC) 871 1 560 1 729 1 270 1 871 1 560 1
+ 1365 Up*** 935 Up*** 1175 Down*** 504 Up*** 1365 Up*** 935 Up*
HER2 (IHC) 1286 1 548 1 1286 1 405 1 1286 1 548 1
+ 175 Nc 134 Nc 175 Nc 122 Down* 175 Down** 134 Nc
TNBC + 356 1 179 1 356 1 116 1 356 1 179 1
3968 Up*** 2494 Up*** 3726 Down*** 1366 Up** 3808 Up* 2381 Nc
Nodal 2375 1 1251 1 2376 1 698 1 2230 1 1251 1
+ 1432 Nc 1064 Up* 1432 Nc 571 Nc 1312 Nc 1064 Nc
  1. Nc No, change; Up upregulation, Down downregualtion, ER estrogen receptor, PR progesterone-receptor, HER2 human epidermal growth factor receptor 2, TNBC triple-negative breast cancer. *p < 0.05, **p < 0.01, ***p < 0.001